The 50 most recent market catalysts affecting $LLY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 65
Eli Lilly Expands Access to Obesity Care via Teladoc Health Partnership
Eli Lilly has announced a partnership with Teladoc Health to offer employers a comprehensive obesity care program. This program will provide employees with access to Lilly's obesit…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly and Stipple Bio Sign Oncology Research and Licensing Agreement
Eli Lilly has announced a strategic research and licensing agreement with Stipple Bio, focusing on precision cancer treatments. This collaboration allows Lilly to leverage Stipple …
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly and Company to Acquire Calytrix Bio
Eli Lilly and Company has entered into a definitive agreement to acquire Calytrix Bio, a developer of precision therapies for myeloproliferative neoplasms (MPNs). This acquisition …
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Adjusts Price Target on Eli Lilly and Company
Barclays, a prominent investment bank, has raised its price target for Eli Lilly and Company from $1,400 to $1,550. This adjustment reflects Barclays' updated analysis of Eli Lilly…
Nov 15, 2026
Corporate Catalyst
Neutral
Impact 65
Eli Lilly Presents New Clinical Data for Cardiometabolic Portfolio at ObesityWeek 2026
Eli Lilly announced new positive clinical trial data for several key cardiometabolic drugs, including Zepbound, retatrutide, and EloraTZP, at ObesityWeek 2026. This matters because…
Nov 13, 2026
Corporate Catalyst
Neutral
Impact 55
EU Regulator Advises Additional Contraception Precautions for Mounjaro Patients
The European Medicines Agency's CHMP has advised that patients taking oral contraceptives with Eli Lilly's Mounjaro should use a backup birth control method for four weeks after st…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Presents New Clinical Data at ACR Convergence 2026
Eli Lilly announced positive Phase 3 clinical trial results for retatrutide in knee osteoarthritis, showing pain reduction over 68 weeks. Additionally, a combination of Taltz and Z…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Breaks Ground on $3.5 Billion Manufacturing Facility in Pennsylvania
Eli Lilly's groundbreaking on a $3.5 billion manufacturing facility signals a significant long-term commitment to scaling production of its high-demand injectable medicines, partic…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Receives Approval in China for Weight-Loss Pill
Eli Lilly has received approval from Chinese regulators for its weight-loss pill, orforglipron, marking a significant milestone as it's the first drugmaker to have a GLP-1 weight-l…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 55
Eli Lilly Launches 'Life Doesn't Slow Down' Campaign for Foundayo
Eli Lilly has initiated a significant marketing push for Foundayo, its once-daily GLP-1 pill for chronic weight management, featuring comedian Leanne Morgan. This campaign is cruci…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Reports Positive Clinical Trial Results for Orforglipron, Originally Discovered by Chugai Pharmaceutical
Eli Lilly announced highly positive clinical trial results for Orforglipron, a GLP-1 receptor agonist, in treating obstructive sleep apnea. The drug significantly reduced breathing…
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 65
FDA Requires Safety Label Updates for GLP-1 Medications
The FDA has mandated that all GLP-1 receptor agonist manufacturers, including major players like Eli Lilly and Novo Nordisk, update their product labels to include a warning about …
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly's Foundayo Meets Primary Endpoint in Phase 3 Sleep Apnea Trial
Eli Lilly reported that its drug Foundayo met its primary endpoint in a Phase 3 clinical trial for obstructive sleep apnea (OSA) in adults with obesity or who are overweight. The d…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Canada Receives Positive Reimbursement Recommendation for Kisunla
Eli Lilly Canada has secured a positive reimbursement recommendation for its Alzheimer's drug, donanemab (marketed as Kisunla), from Canadian authorities. This is a crucial develop…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Analyst Increases Price Target for Eli Lilly
This 8-K filing discloses that analyst Akash Tewari has raised the price target for Eli Lilly (LLY) from $1,610 to $1,700, while keeping a 'buy' rating. This action reflects an upd…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Partners with Hims & Hers to Offer Obesity Drugs, Increasing Competition with Novo Nordisk
Eli Lilly has announced a partnership with telehealth provider Hims & Hers, enabling direct-to-consumer sales of its obesity drugs, Zepbound and Foundayo. This is a significant str…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 65
Eli Lilly and Hims & Hers Announce Agreement to Expand Access to Obesity Medications
Eli Lilly and Hims & Hers have formed a strategic partnership to make Lilly's FDA-approved obesity medications, Zepbound and Foundayo, available through the Hims & Hers telehealth …
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly Enters Agreement with Hims & Hers to Expand Access to Obesity Medications
Eli Lilly announced a strategic partnership with Hims & Hers to distribute its blockbuster obesity drugs, Zepbound and Foundayo, through the telehealth platform. This is a signific…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
BofA Securities Raises Eli Lilly Price Target
BofA Securities has raised its price target for Eli Lilly (LLY) from $1,497 to $1,557, while reiterating its 'Buy' rating. This indicates a strengthened conviction from the analyst…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 55
Lilly to Present New Clinical Data on Retatrutide, Taltz, and Zepbound at ACR Convergence 2026
Eli Lilly is announcing its upcoming presentations at the ACR Convergence 2026 conference, focusing on new clinical and real-world data for retatrutide, Taltz, and Zepbound. This m…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 75
Eli Lilly Provides Update on Foundayo Development
Eli Lilly's announcement details its strategic plan for Foundayo, a new drug aimed at the cardiometabolic market. The company expects a broad international launch by 2027 and has a…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 65
Berenberg Adjusts Price Target on Eli Lilly and Company to $1,570
Berenberg has raised its price target for Eli Lilly and Company to $1,570, up from $1,400. This adjustment is a direct result of Eli Lilly's better-than-expected third-quarter earn…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Adjusts Price Target on Eli Lilly to $1,600
Cantor Fitzgerald raised its price target on Eli Lilly to $1,600, up from $1,440, following a positive re-evaluation of the company's market position and growth prospects. This upg…
Nov 1, 2026
Corporate Catalyst
Neutral
Impact 55
Lilly Endowment Inc. Proposes Sale of Eli Lilly Common Stock
Lilly Endowment Inc., a significant long-term shareholder, is continuing its divestment from Eli Lilly and Company. This filing discloses an additional planned sale of 295,000 shar…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 75
Analysts Raise Price Targets for Eli Lilly Following Q3 Results
Eli Lilly's Q3 2026 earnings report has prompted leading financial analysts, UBS and BMO, to significantly raise their price targets for the company. This upward revision, accompan…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Raises Price Target on Eli Lilly to $1,600 From $1,500
RBC Capital Markets has raised its price target on Eli Lilly to $1,600 from $1,500, while reiterating an Outperform rating. This adjustment is a direct response to Eli Lilly's impr…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Adjusts Price Target on Eli Lilly to $1,612
Truist has raised its price target for Eli Lilly to $1,612 from $1,376, maintaining its Buy rating. This indicates a stronger conviction from the analyst firm regarding Eli Lilly's…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 75
JPMorgan Raises Price Target on Eli Lilly to $1,650
JPMorgan raised its price target on Eli Lilly to $1,650, signaling increased confidence in the company's long-term earnings potential. This positive outlook is primarily driven by …
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 95
Eli Lilly Reports Strong Third-Quarter 2026 Financial Results
Eli Lilly announced exceptional third-quarter 2026 financial results, significantly exceeding analyst expectations for both revenue and adjusted earnings per share. This outperform…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
Eli Lilly Licenses SpeechDx Dataset for Alzheimer's Research
Eli Lilly has licensed the SpeechDx dataset, a significant collection of speech and biomarker data related to Alzheimer's disease. This is a strategic move to advance their researc…
Oct 28, 2026
Corporate Catalyst
Neutral
Impact 55
Eli Lilly Licenses SpeechDx Dataset, Joining Siemens Healthineers in Alzheimer's Research
Eli Lilly's licensing of the SpeechDx dataset signifies a strategic move to bolster its Alzheimer's research and drug development efforts. By leveraging this dataset alongside trad…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly Announces Positive Phase 3 Results for Retatrutide in Type 2 Diabetes
Eli Lilly's retatrutide, a triple-agonist, has shown superior efficacy against Novo Nordisk's Ozempic (semaglutide) in a head-to-head Phase 3 trial for Type 2 Diabetes. This is a s…
Oct 27, 2026
Corporate Catalyst
Neutral
Impact 65
Eli Lilly and Company Announces Executive Leadership Changes
Eli Lilly announced the retirement of Patrik Jonsson, EVP and President of Lilly International, effective end of 2026. Concurrently, the company will consolidate its U.S. and inter…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Raises Price Target for Eli Lilly
Bernstein, a financial services firm, has raised its price target for Eli Lilly (LLY) from $1,385 to $1,450. This adjustment is a standard analyst action based on their updated val…
Oct 24, 2026
Corporate Catalyst
Bullish
Impact 75
Lilly Announces Positive Phase 1 Data for Investigational ADC Sofetabart Mipitecan in Ovarian Cancer
Eli Lilly announced positive Phase 1 data for its investigational antibody-drug conjugate (ADC), sofetabart mipitecan, in combination with bevacizumab for platinum-sensitive ovaria…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly and Company Breaks Ground on $5B Integrated Manufacturing Site in Virginia
Eli Lilly has broken ground on a $5 billion integrated manufacturing site in Virginia, a significant investment aimed at producing active pharmaceutical ingredients (APIs) and anti…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 55
Mubadala Bio and Lilly Announce Landmark Agreement to Advance Pharmaceutical Contract Manufacturing in Abu Dhabi
Eli Lilly and Mubadala Bio have formed a strategic partnership to localize the packaging and logistics for Lilly's GLP-1 medicines in Abu Dhabi. This agreement signifies Lilly's co…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 75
Eli Lilly’s Omvoh Shows 1-Year Phase 3 Results for Kids with Ulcerative Colitis
Eli Lilly reported strong one-year Phase 3 results for Omvoh in pediatric ulcerative colitis, with 50% of responders achieving clinical remission. This is significant because Omvoh…
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly's Foundayo, an oral GLP-1 receptor agonist, has received a positive opinion from the European CHMP, a crucial step towards full marketing authorization in the EU. This de…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly shares are trading higher after the company reported new data showing Omvoh helped patients with ulcerative colitis and Crohn's disease achieve multiple treatment goals at one year.
This headline represents a significant positive catalyst for Eli Lilly, as strong clinical trial data for a major drug like Omvoh can lead to increased market share, higher revenue…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 85
Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients
Eli Lilly released new, positive clinical data for its drug Omvoh, showing comprehensive disease control in ulcerative colitis and deep remission in Crohn's disease. This is a sign…
Oct 15, 2026
Corporate Catalyst
Bearish
Impact 55
U.K.'s Medicines And Healthcare Products Regulatory Agency Announces It Seized More Than 12K Fake Retatrutide And Tirzepatide Pens Along With Packaging For ~30K More Products In Birmingham On Oct. 14
The MHRA's seizure of 12,000 fake Retatrutide and Tirzepatide pens, along with packaging for 30,000 more, underscores the escalating issue of counterfeit weight-loss drugs. This ma…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 65
Lilly Reports Omvoh Achieved Multiple Treatment Goals Simultaneously At One Year In IBD Studies
Eli Lilly announced new data analyses for its drug Omvoh, showing it achieved multiple treatment goals simultaneously in patients with ulcerative colitis and Crohn's disease. This …
Oct 14, 2026
Market Technicals
Neutral
Impact 55
Watching Eli Lilly; Hearing Investor Business Daily SwingTrader Buys Stock
The headline highlights a 'buy' signal from Investor Business Daily SwingTrader for Eli Lilly. This is a technical indicator, not a fundamental change in the company's prospects, b…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 65
U.K. Medicines And Healthcare Products Regulatory Agency Authorizes Eli Lilly's Onswik For Adults With Type 2 Diabetes
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized Eli Lilly's Onswik (efsitora alfa) for adults with Type 2 diabetes. This approval signifies a new m…
Oct 9, 2026
Corporate Catalyst
Neutral
Impact 65
Eli Lilly Presents New Exploratory Data From The TOGETHER-PSO Phase 3B Clinical Trial Taltz And Zepbound Compared With Taltz Alone In Adults With Moderate-To-Severe Plaque Psoriasis And Obesity Or Overweight; Data Showed Broader Biomarker Changes With Taltz And Zepbound Vs Taltz Alone
Eli Lilly presented new exploratory biomarker data from its TOGETHER-PSO Phase 3b clinical trial. The findings suggest that combining Taltz (for psoriasis) and Zepbound (for obesit…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 85
Transcript: Eli Lilly Q2 2026 Earnings Conference Call
Eli Lilly's Q2 2026 earnings call transcript reveals a very strong quarter with 48% revenue growth year-over-year and a significant increase in key product sales, especially in onc…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440
Cantor Fitzgerald's analyst Carter Gould has raised the price target for Eli Lilly (LLY) from $1410 to $1440 while maintaining an 'Overweight' rating. This action reflects an updat…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.